News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Oncology Sponsored Global oncology innovation from Hengrui Pharma Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.
News GSK shares come under pressure from weaker vaccine sales Shares in GSK fell on a decline in vaccine sales in Q3, although demand for other drugs was strong with signs that its revamp is starting to deliver.
News ESMO26: Ris-rez offers hope of osteosarcoma breakthrough There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
News ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.
Oncology Sponsored 12 Questions with Julia Jakl Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.